口服版司美格鲁肽大降价,诺和诺德“死磕”礼来

健识局
Feb 26

2月26日,青海省药品采购中心发布《关于调整部分药品价格的通知》,口服司美格鲁肽片剂出现在降价名单中。图源:青海省药品采购中心诺和诺德的司美格鲁肽口服制剂是目前全球唯一获批的口服GLP-1药物,与注射剂型相比,片剂无需冷链运输,患者便利性和依从性更高,市场普及度更广。2024年1月,诺和诺德的司美格鲁肽口服片剂在中国获批上市,只适用于治疗2型糖尿病。但就算是“全世界独一份”的品种,诺和诺德也不打算...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10